Abstract
Despite its decreasing incidence overall, gastric cancer is still a challenging disease. Therapy is based mainly upon surgical resection when the tumour remains localised in the stomach. Conventional chemotherapy may play a role in treating micrometastatic disease and is effective as palliative therapy for recurrent or advanced disease. However, the knowledge of molecular pathways implicated in gastric cancer pathogenesis is still in its infancy and the contribution of molecular biology to the development of new targeted therapies in gastric cancer is far behind other more common cancers such as breast, colon or lung. This review will focus first on the difference of two well defined types of gastric cancer: intestinal and diffuse. A discussion of the cell of origin of gastric cancer with some intriguing data implicating bone marrow derived cells will follow, and a comprehensive review of different genetic alterations detected in gastric cancer, underlining those that may have clinical, therapeutic or prognostic implications.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
Author information
Authors and Affiliations
Corresponding author
Additional information
*Supported by an unrestricted educational grant from Sanofi-Aventis.
Rights and permissions
About this article
Cite this article
Cervantes, A., Rodríguez Braun, E., Pérez Fidalgo, A. et al. Molecular biology of gastric cancer. Clin Transl Oncol 9, 208–215 (2007). https://doi.org/10.1007/s12094-007-0041-4
Issue Date:
DOI: https://doi.org/10.1007/s12094-007-0041-4